Article de Périodique
Zero tolerance for 0%? How should clinicians and other practitioners respond to the use of alcohol-free and low-alcohol products in higher risk groups [Addiction opinion and debate] (2026)
Auteur(s) :
HOLMES, J. ;
OLDROYD, C. K. ;
DRUMMOND, C. ;
FIELD, M. ;
KERSBERGEN, I. ;
ALLISON, M. E. D.
Année
2026
Page(s) :
1036-1041
Sous-type de document :
Revue de la littérature
Langue(s) :
Anglais
Refs biblio. :
51
Domaine :
Alcool
Discipline :
SAN (Santé publique / Public health)
Thésaurus mots-clés
ALCOOL
;
BOISSON SANS ALCOOL
;
USAGE PROBLEMATIQUE
;
RECOMMANDATION
;
FOIE
;
PRISE EN CHARGE
;
TRAITEMENT
;
PERSONNEL MEDICAL
;
BENEFICE
;
FACTEUR DE RISQUE
;
PHENOMENE EMERGENT
;
SANTE PUBLIQUE
;
REDUCTION DE CONSOMMATION
;
CRAVING
;
REDUCTION DES RISQUES ET DES DOMMAGES
Note générale :
Commentaries:
Bowdring M.A. (2026) Could alcohol-free and low-alcohol beverages be used to extinguish alcohol cravings? p. 1042-1043. https://doi.org/10.1111/add.70295
Sinclair J.M.A. (2026) Seeing through a glass darkly. p. 1044-1045. https://doi.org/10.1111/add.70343
Holmes J., Field M., Drummond C. (2026) Examining definitions and cues associated with alcohol-free and low-alcohol drinks. p. 1046-1047. https://doi.org/10.1111/add.70408
Résumé :
Alcohol-free and low-alcohol drinks (no/lo drinks) are now widely available and popular with consumers in high-income countries; however, it is unclear whether clinicians and others working to prevent or treat severe alcohol-related health problems should take a zero-tolerance approach to these alcohol-like products or encourage patients to try them. We argue that no/lo drinks may have an important role to play for people who drink at high-risk levels and those with alcohol use disorders (AUD) or alcohol-related liver
disease (ARLD), particularly where debate and guidance related to treatment of these problems considers goals other than abstinence. The limited available evidence available suggests no/lo drinks may be useful in supporting attempts to reduce alcohol consumption or maintain abstinence among high-risk drinkers who do not have severe AUD or ARLD; however, they may also entail significant risks of relapse in those recovering from AUD. We therefore need further experimental and longitudinal studies testing whether use of no/lo drinks can lead to, or support, reductions in alcohol consumption. We particularly need high-quality experimental studies to test whether exposure to and sustained use of no/lo drinks affects treatment and recovery outcomes. Evidence is also needed on which subgroups of AUD and ARLD patients would benefit or be at risk from use of either alcohol-free or low-alcohol drinks. Finally, guidance should recognise that many patients already use these products and that a zero-tolerance approach may alienate patients or erode trust in clinicians. [Author's abstract]
disease (ARLD), particularly where debate and guidance related to treatment of these problems considers goals other than abstinence. The limited available evidence available suggests no/lo drinks may be useful in supporting attempts to reduce alcohol consumption or maintain abstinence among high-risk drinkers who do not have severe AUD or ARLD; however, they may also entail significant risks of relapse in those recovering from AUD. We therefore need further experimental and longitudinal studies testing whether use of no/lo drinks can lead to, or support, reductions in alcohol consumption. We particularly need high-quality experimental studies to test whether exposure to and sustained use of no/lo drinks affects treatment and recovery outcomes. Evidence is also needed on which subgroups of AUD and ARLD patients would benefit or be at risk from use of either alcohol-free or low-alcohol drinks. Finally, guidance should recognise that many patients already use these products and that a zero-tolerance approach may alienate patients or erode trust in clinicians. [Author's abstract]
Affiliation :
School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre, Cambridge, UK.
Cambridge Liver Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
School of Psychology, University of Sheffield, Interdisciplinary Centre of the Social Sciences (ICOSS) Building, Sheffield, UK.
National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre, Cambridge, UK.
Cambridge Liver Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
School of Psychology, University of Sheffield, Interdisciplinary Centre of the Social Sciences (ICOSS) Building, Sheffield, UK.
Cote :
Abonnement électronique
Historique